Overexpression of fibroblast growth factor receptor (FGFR) tyrosine kinases has been found in many human breast cancers and has been associated with poor patient prognosis. In order to understand the mechanism by which FGFR mediates breast cancer cell proliferation, we used a low molecular weight compound, PD173074, that selectively inhibits FGFR tyrosine kinase activity and autophosphorylation. This potential anticancer agent caused a G1 growth arrest of MDA-MB-415, MDA-MB-453 and SUM 52 breast cancer cells. Our analyses revealed that FGFR signaling links to the cell cycle machinery via D-type cyclins. PD173074-mediated inhibition of FGFR activity caused downregulation of cyclin D1 and cyclin D2 expression, inhibition of cyclin D/cdk4 activity and, as a consequence, reduction of pRB phosphorylation. Retroviral-mediated ectopic expression of cyclin D1 prevented pRB hypophosphorylation and the cell cycle G1 block in PD173074-treated cells, suggesting a central role for D cyclins in proliferation of FGFR-driven breast cancer cells. The repression of FGFR activity caused downregulation of MAPK in MDA-MB-415 and MDA-MB-453 cells. In SUM 52 cells, both MAPK and PI3K signaling pathways were suppressed. In conclusion, results shown here describe a mechanism by which FGFR promotes proliferation of breast cancer cells.
Introduction
Fibroblast growth factor receptors (FGFRs) are glycoproteins composed of extracellular immunoglobulin (Ig)-like domains, a hydrophobic transmembrane region and a cytoplasmic part containing a tyrosine kinase domain. The FGFR family consists of five members -FGFR-1, FGFR-2, FGFR-3, FGFR-4 and FGFR-5 -some of which generate multiple products via alternative splicing (Klint and Claesson-Welsh, 1999; Kim et al., 2001) . These receptors mediate signaling from their highaffinity ligands, fibroblast growth factors (FGFs) (Ornitz and Itoh, 2001) . FGF binding leads to FGFR dimerization, followed by receptor autophosphorylation and activation of downstream signaling pathways. In addition, heparin and heparan sulfate proteoglycans (HSPG) modulate ligand binding to the receptor tyrosine kinase (Plotnikov et al., 2000) .
Active FGFRs stimulate tyrosine phosphorylation and activation of a number of signaling molecules: Shc, PI3K, Src, PLCg, Crk, SH2 domain containing phosphatase-2 (SHP-2), p38, STAT1/3 and FGFR substrate 2 (FRS2) (Klint and Claesson-Welsh, 1999) . Phosphorylation of the docking protein FRS2 recruits and activates the Grb2/Sos1 complex, which then interacts with Ras to activate the MAPK pathway (Kouhara et al., 1997; Ong et al., 2000) . This signaling pathway has been shown to contribute to FGFR-mediated cell proliferation and migration (Klint and Claesson-Welsh, 1999; Boilly et al., 2000) . Activation of the PI3K pathway downstream of FRS2 is involved in cell motility (Cross et al., 2000) and survival (Ong et al., 2001) .
FGFRs are involved in multiple biological processes ranging from cell transformation, angiogenesis and tissue repair to embryonic development (Basilico and Moscatelli, 1992; Werner et al., 1994; Cross and ClaessonWelsh, 2001 ). Moreover, FGFRs play important roles during mammary gland differentiation in processes of ductal and alveolar formation, where FGFRs expression is associated with highly proliferative state (Chodosh et al., 2000) . While FGFR signaling is clearly important in physiological processes, aberrant regulation of FGF ligands and their receptors is associated with cancer. In particular, amplifications and overexpression of FGFRs, including FGFR-1 (20%), FGFR-2 (12%) and FGFR-4 (30%), has been observed in breast cancers (Adnane et al., 1991; Jaakkola et al., 1993; Theillet et al., 1993; Penault-Llorca et al., 1995) . Upregulation of FGFs and FGFR has also been reported in astrocytomas (Yamaguchi et al., 1994) , melanomas (Yayon et al., 1997) , pancreatic (Kornmann et al., 1997) , prostate (Giri et al., 1999) , ovarian (Valve et al., 2000) , gastric and colorectal cancers (Jang et al., 2001) .
Although there are correlations between the expression of FGFRs and breast cancer progression, their role in tumorigenesis is still not fully understood and may, in fact, be multiple. Indeed, while FGFRs have a welldocumented function in angiogenesis and migration (Gerwins et al., 2000; Suyama et al., 2002) , the mechanism of FGFR-mediated cell proliferation has not yet been elucidated. In the present work, we investigated the effect of blocking FGFR signaling on proliferation of breast cancer cells. In order to inhibit signaling, we used PD173074, a low molecular weight compound that selectively blocks the tyrosine kinase activity of FGFR (Mohammadi et al., 1998) . We found that repression of FGFR activity leads to an accumulation of MDA-MB-453, MDA-MB-415 and SUM 52 breast cancer cells in the G1 phase of the cell cycle, causing a strong proliferative block. Following PD173074 treatment, the MAPK pathway is downregulated in all three breast cancer cells, additionally the PI3K pathway is blocked in SUM 52 cells. The mechanism underlying PD173074's antiproliferative activity downstream of MAPK and PI3K signaling appears to be via decreased expression of cyclin D1 and cyclin D2 and, as a consequence, pRB hypophosphorylation. By rescuing cells from the PD173074-mediated cell cycle block, we further provide evidence that D-type cyclins are key players regulating FGFR-dependent proliferation in breast cancer cells.
Results

PD173074 blocks phosphorylation of FGFRs in human breast cancer cells
In order to understand the molecular role of FGFR in breast cancer cell proliferation, we first screened breast cancer cell lines for their FGFR expression profile. MDA-MB-415, MDA-MB-453 and SUM 52 were found to express at least two FGFR members, while there were no detectible FGFRs in the control MCF10A normal breast cell line (Figure 1a ). The level of FGFR-3 expression was equivalent in the three tumor cell lines. FGFR-4, while present in all three, was dramatically overexpressed in MDA-MB-453 cells. In addition to FGFR-3 and -4, SUM 52 cells also showed FGFR-2 expression ( Figure 1a ). FGFR1 protein was not detectable in any of the examined cell lines (data not shown). Activity of each FGFR was examined after immunoprecipitation and probing for phosphotyrosine content. Depending on the tumor cell line, FGFR-4 displayed moderate to high levels of phosphotyrosine (Figure 1b) . Additionally, SUM 52 cells had constitutive activation of FGFR-2 (Figure 1b ). There was no detectable tyrosine phosphorylation of FGFR-3 in any of these cell lines (data not shown). PD173074, a small molecular weight inhibitor of FGFRs (Mohammadi et al., 1998) , was tested for its effects on FGFR activity. PD173074 efficiently downregulated phosphorylation of both FGFR-2 and FGFR-4 in the examined cell lines (Figure 1b) .
Inhibition of FGFR activity in breast cancer cells leads to G1 accumulation and suppresses proliferation
We next examined the effect of blocking FGFR activity on proliferation of the breast cancer cell lines. PD173074 treatment suppressed growth of MDA-MB-453 and MDA-MB-415 cells by approximately 70%, while SUM 52 cells were completely blocked (Figure 2a) . Importantly, the MCF10A control cell line, which has no FGFR expression, was not affected by PD173074. This result, combined with our observation that the phosphorylation of the ErbB2 and ErbB3 receptors in MDA-MB-453 and SUM 52 is not affected by PD173074 (data not shown), attests to the inhibitor's specificity.
To further explore the antiproliferative effects of the FGFR-directed inhibitor, we performed flow cytometry analysis. Treatment with PD173074 led to an accumulation of MDA-MB-415, MDA-MB-453 and SUM 52 cells in the G1 phase of the cell cycle (Figure 2b ), without evidence of apoptosis. In accordance with the proliferation results, MCF10A cell cycle profile was not affected by PD173074 treatment. These data suggest that FGFR signaling is directly involved in proliferation by driving progression of the cancer cells from G1 to the S phase of the cell cycle.
Downregulation of FGFR activity affects MAPK and PI3K signaling
The MAPK and PI3K pathways, which are the major signaling cascades downstream of the FGFRs, were After immunoblotting with a phosphotyrosine-specific antibody (PTyr), the membranes were reprobed to control for FGFR-4 and FGFR-2 protein levels FGFR-mediated breast cancer cell proliferation M Koziczak et al examined after PD173074 treatment. As a read-out for the activation status of each pathway, we performed Western blotting analyses using phospho-ERK1/2 and phospho-PKB antibodies, respectively. All breast cancer cell lines exhibited relatively high activity of both pathways. Correlating the inhibitor's effect on FGFR activity (Figure 1b) , the level of phospho-ERK1/2 was significantly reduced in the three cell lines following PD173074 treatment (Figure 3 ). In contrast, sustained reduction in the level of phospho-PKB was only observed in SUM 52 cells. Thus, FGFR drives activation of the MAPK pathway in the three tumor cell lines, while only in the latter a link between FGFR and the PI3K pathway was observed. For further analyses, we examined the effect of PD173074 on MDA-MB-453 and SUM 52 cells, as an example of each type.
FGFRs control the G1 to S transition via cyclin D/cdk4-mediated phosphorylation of pRB
To gain insight into the molecular mechanism underlying the PD173074-mediated G1 accumulation in the tumor cells, we examined the phosphorylation status of the retinoblastoma protein (pRB). pRB phosphorylation is a critical step in the G1 to S phase transition (Sherr, 1996) . Phosphorylation of pRB is controlled primarily by complexes of D cyclins associated with cdk4/6 and later by cyclin E associated with cdk2 (Sherr and Roberts, 1999) . Western blot analyses on extracts from PD173074-treated cells revealed a shift down in the pRB protein, a sign of hypophosphorylation ( Figure 4a ). Reprobing of the blots with a phospho-pRB-specific antibody showed that pRB from MDA-MB-453 and SUM 52 cells had decreased phosphorylation on serine 795. In contrast, the phosphorylation status of pRB in control MCF10A cells was not affected by PD173074 treatment. These data suggest that FGFR signaling controls cell proliferation by regulating pRB phosphorylation. pRB serine 795 is a target of active cyclin D/cdk4 complexes (Connell-Crowley et al., 1997) . The observed decrease in its phosphorylation prompted us to examine expression of D-type cyclins in these cells. Following PD173074 treatment, expression of cyclin D1 and cyclin D2 was reduced in both breast tumor cell lines (Figure 4b ). Analysis of cdk4 and cdk6, partners of D cyclins, demonstrated no changes in their expression. (Cdk 6 was not detectable in MDA-MB-453 cells.) Corresponding with the loss of D cylins, there was a decrease in cdk4 activity detected by in vitro kinase assay using pRB as a substrate (Figure 4c ). Taken together, these results indicate that in MDA-MB-453 and SUM 52 cells, FGFR controls activity of cyclin D1(D2)/cdk4(6) complexes by limiting expression of D-type cyclins. This in turn leads to hypophosphorylation of pRB, a block in G1 phase of cell cycle and an inhibition of proliferation.
FGFR controls cyclin D1 expression at the transcriptional level
Expression of D-type cyclins is controlled at both the mRNA (Albanese et al., 1995) and protein (Diehl et al., 1998) levels. In order to define how PD173074 treatment leads to the observed decrease in D-type cyclins, we concentrated on cyclin D1, examining its mRNA level after treatment with the inhibitor. Northern blot analyses revealed two cyclin D1 transcripts in the cells. MDA-MB-453 cells express mainly a truncated cyclin D1 mRNA, which is known to have greater stability than the full-length mRNA (Lebwohl et al., 1994) . High levels of this truncated transcript, which bears a large deletion in its 3 0 UTR, have been seen in different tumors (Rimokh et al., 1994) . FGFR inhibition rapidly caused downregulation of both cyclin D1 transcripts in MDA-MB-453 as well as in SUM 52 cells (Figure 5a ), which likely explains the decrease in protein expression (Figure 4b) . Accordingly, PD173074 treatment reduced luciferase activity driven from a cyclin D1 promoter by approximately 30% in MDA-MB-453 cells and 50% in SUM 52 cells (Figure 5b) . Together, these results (2 mM). Cells were harvested at indicated times and protein lysates were analysed by immunoblotting with phospho-specific antibodies against ERK1/2 (ERK1/2-P) and PKB (PKB-P). The membranes were reprobed to control for ERK1/2 and PKB protein levels Figure 4 Analysis of G1 regulators in FGFR inhibitor-treated cells. MDA-MB-453, SUM 52 and MCF10A cells were treated with PD173074 (2 mM) for the indicated period of time and cell lysates were prepared. (a) The phosphorylation status of pRB was determined by immunoblotting with an antibody specific for pRB protein (pRB) or for pRB phosphorylated on serine 795 (pRB-P). (b) The protein levels of cyclin D1, cyclin D2, cyclin D3, cdk4 and cdk6 were evaluated by immunoblotting with specific antibodies. Equivalent loading was confirmed by reprobing with antitubulin antibody. (c) cdk4 kinase activity was measured using RB GST-Rb as a substrate. The radioactivity of specific bands was determined and the values from two experiments are shown as percent (%). Values are the mean7s.e.
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suggest that cyclin D1 expression downstream of FGFR is mainly controlled at the transcriptional level.
Ectopic expression of cyclin D1 rescues the PD173074-induced G1 arrest
To verify the central role of D-type cyclins in FGFRregulated breast cancer cell proliferation, we performed a rescue experiment, ectopically expressing cyclin D1 in PD173074-blocked cells. MDA-MB-453 and SUM 52 cells were infected with retroviruses expressing EGFP or cyclin D1 upstream of IRES-EGFP. The infection efficiency for both viruses was B65% in MDA-MB-453 cells and B80% in SUM 52 cells. Infected cells had increased cyclin D1 protein levels, and SUM 52 cells expressed more cyclin D1 than MDA-MB-453 cells (Figure 6a ), which might be due to differences in posttranscriptional regulation between the two cell lines. As expected, control cultures treated with PD173074 showed loss of cyclin D1 and decreased pRB phosphorylation. In contrast, ectopically expressed cyclin D1 was insensitive to PD173074 treatment. Importantly, the level of phosphorylated pRB remained high in the PD173074-treated cells and the cells were rescued from the antiproliferative effects of the kinase inhibitor ( Figure 6b ). Despite ectopic expression of cyclin D1, the MAPK signaling was strongly reduced in PD173074-treated cultures, proving a direct involvement of overexpressed cyclin D1 in preventing the cell cycle block. These results strengthen those obtained in the proceeding sections, by directly showing the central role of cyclin D1 in driving FGFR-mediated proliferation of MDA-MB-453 and SUM 52 tumor cells.
Discussion
Overexpression of FGFRs occurs frequently in human breast tumors and correlates with poor prognosis and shorter survival time. In the present study, we examined the mechanism by which FGFR activity contributes to cell proliferation. We showed that treatment of breast cancer cells, expressing active FGFR, with the FGFRselective inhibitor, PD173074, affects cell's main mitogenic pathways and G1 cell cycle regulators. Elevated levels of cyclin D1 are believed to contribute directly to tumorigenicity, and several lines of evidence suggest an important role for cyclin D1 in breast cancer FGFR-mediated breast cancer cell proliferation M Koziczak et al formation (Wang et al., 1994; Hosokawa and Arnold, 1998) . Cyclin D1 amplification has been found in 20% of human breast cancer (Dickson et al., 1995) and overexpression of cyclin D1 protein has been reported in 50% of human mammary carcinomas (Bartkova et al., 1994) . Interestingly, it has also been shown that in primary breast tumors, coamplifications of CCND1 and FGFR1 were associated with a significant reduction in patient survival (Cuny et al., 2000) , suggesting a biological interaction between these two proteins. We show here that PD173074's inhibitory effect on cell cycle progression is due to a rapid downregulation of cyclin D1 and cyclin D2 expression and in turn pRb hypophosphorylation. Our data show that treatment of tumor cells with the FGFR inhibitor leads to reduction in pRb phosphorylation on serine 795, a site that is known to be phosphorylated by the cyclin D/cdk4 complex. Indeed activity of this complex was suppressed upon PD173074 treatment. Thus, it appears that the FGFR signaling promotes cell proliferation by upregulating cyclin D levels, a model strongly supported by our result showing that ectopic cyclin D1 expression is able to rescue the PD173074-mediated antiproliferative effect. In addition to cyclin availability, the cyclin/cdk complex activity is also negatively regulated by association with cyclin kinase inhibitors (CKIs) (Morgan, 1995) . However, in MDA-MB-453 cells, p27 expression was significantly increased only at later times (24 h, data not shown), suggesting that the increase in p27 levels might be a consequence rather than a cause of the cell cycle block.
An interesting issue was to determine how downregulation of FGFR signaling caused a reduction in cyclin D1 protein levels. D cyclin expression can be regulated at the transcriptional (Nagata et al., 2001 ) and the translational (Diehl et al., 1998) levels. Using a cyclin D1 reporter gene we found that the FGFR inhibitor caused a significant reduction in promoter activity, which was reflected in the overall decrease in cyclin D1 mRNA. Moreover, in contrast to endogenous cyclin D1, ectopically expressed protein was insensitive to PD173074 treatment, suggesting that inhibitormediated decrease in endogenous cyclin D1 was mainly due to transcriptional regulation. At the post-translational level, proteosome degradation has been reported to be an essential component in the control of D cyclin expression (Diehl et al., 1998) . However, PD173074 did not affect cyclin D2 protein stability as determined by pulse-chase experiments (data not shown). These results further support that in breast cancer cells active FGFRs have a major role in controlling cyclin D transcription. Numerous transcription factors have been reported to participate in regulating cyclin D expression: Ets (Albanese et al., 1995) , E2F (Lavia and Jansen-Durr, 1999) , Sp1 (Nagata et al., 2001) , CREB (Nagata et al., 2001) , c-jun (Albanese et al., 1995) , STAT5 (Matsumura et al., 1999) , NFkB (Guttridge et al., 1999) and c-myc (Daksis et al., 1994) . c-myc plays a major role in the regulation of normal cell proliferation and is aberrantly expressed in many human cancers. Inhibition of FGFR caused a decrease in c-myc levels in cell lines we examined (data not shown), suggesting that, among other transcription factors, c-myc might be involved in FGFR-mediated breast cancer cell proliferation.
The MAPK and PI3K pathways, important effectors of FGFR-stimulated signaling (Klint and ClaessonWelsh, 1999) , are also upstream regulators of c-myc and D-type cyclins. Therefore, we tested activity of these pathways following PD173074 treatment of breast cancer cells. Indeed, ERK1/2 phosphorylation was strongly reduced in all the examined FGFR-positive cell lines. Moreover, the PI3K pathway was dramatically downregulated in SUM 52 cells. Despite the fact that PKB has been shown to mediate FGFR-regulated cell survival (Ong et al., 2001 ), we did not detect apoptosis in PD173074-treated SUM 52 cells.
We conclude that proliferation of the MDA-MB-415, MDA-MB-453 and SUM 52 breast cancer cells depends mainly on FGFR-regulated pathways. FGFR-mediated signaling is linked to the cell cycle machinery through regulation of the D-type cyclins. Our results suggest that this receptor tyrosine kinase family represents another exciting target for anticancer therapeutic agents. In particular, FGFR inhibitors might be potent therapeutic agents not only to suppress angiogenesis, but also to inhibit growth of a subset of breast tumors.
Materials and methods
Growth factors, inhibitors, antibodies
The FGFR inhibitor, PD173074 (Mohammadi et al., 1998) 
Cell culture
MDA-MB-415 and MDA-MB-453 human breast cancer epithelial cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco-BRL) supplemented with 10% (v/v) fetal calf serum (FCS, Life Technologies) at 371C in a humidified CO 2 (5%) incubator. MCF10A human breast epithelial cells were cultured in a 1 : 1 mixture of Ham's F-12 medium : DMEM supplemented with 10% FCS. SUM 52 human breast cancer cells, obtained from S Ethier, were maintained in Ham's F-12 medium containing 2% FCS and supplemented as described previously (Ethier et al., 1993) .
Proliferation assay and flow cytometry
To determine cell proliferation, MDA-MB-415, MDA-MB-453 and MCF10A cells were plated in 96-well plates and after 24 h (h) treated with DMSO or PD173074 (2 mM). Cell growth was assayed with the MTT Cell Proliferation Kit I (Roche) after 0, 4 and 8 days of inhibitor treatment. SUM 52 cells were plated in six-well plates and after 24 h DMSO or PD173074 (2 mM) was added. After 4 and 8 days, cultures were trypsinized FGFR-mediated breast cancer cell proliferation M Koziczak et al and the cells were counted in a hemocytometer. Each assay was carried out in triplicate. To analyse cell cycle profiles, MDA-MB-415, MDA-MB-453, SUM 52 and MCF10A cells were plated on 10 cm plates. After 24 h, cells were treated with DMSO or PD173074 (2 mM). After 24 or 48 h (for SUM 52), cells were trypsinized and processed as described before (Neve et al., 2002) . Cell cycle profiles of EGFP-expressing cells were analysed as described (Holbro et al., 2003) .
Western blot analysis
Cell lysate preparation, immunoprecipitations and Western analyses were carried out by standard procedures, as described previously . Signals were detected by enhanced chemiluminescence (ECL; Amersham).
RNA isolation and Northern blot analysis
MDA-MB-453 and SUM 52 cells were plated on 6 cm plates. After 24 h, cells were treated with DMSO or PD173074 (2 mM) and harvested at the indicated times. Total RNA (10 mg) was prepared with Trizol reagent (Invitrogen). Northern blot analysis was performed as described (Koziczak et al., 2000) . cDNA clone for human cyclin D1 (obtained from B Amati) was used as a probe. The mouse b actin probe was obtained from Ambion. Levels of specific RNA were measured in a Molecular Dynamics PhosphoImager.
Transient transfection assays
MDA-MB-453 and SUM 52 cells were plated in six-well plates and transfected using the SuperFect Transfection Reagent (Qiagen). 2 mg of the -1748 CD1 plasmid (cyclin D1 promoter in pGL3; provided by F McCormick and O Tetsu) (Tetsu and McCormick, 1999) and 50 ng of the pRLSV40 plasmid were used per well. After 5 h, the SuperFect reagent was washed off and cells were incubated with DMSO or PD173074 (2 mM) for 24 h. Cell extracts were assayed for luciferase activity with the Dual-Luciferase Reporter Assay System (Promega) using a Luminometer (Autolumat LB 953, Berthold).
Rb kinase assay
MDA-MB-453 cells were plated on 6 cm plates. After treatment with PD173074, cell lysates were prepared and kinase assays were performed as described .
Retroviral vectors and infections
MFG-IRES-EGFP plasmid was made as described before (Holbro et al., 2003) . Cyclin D1 was blunt-cloned into the XhoI site of MFG-IRES-EGFP. Retroviral infections were carried out as described (Holbro et al., 2003) .
